Index of /pdfs/packageinserts

      Name                    Last modified       Size  Description


[DIR] Parent Directory        16-Jun-2004 11:50      -  
[   ] pt_conversion.pdf       06-Jul-2001 12:36   337k  
[   ] pt.pdf                  27-Jun-2001 15:10   580k  
[   ] pt-one_conversion.pdf   06-Jul-2001 12:35   337k  
[   ] pt-one.pdf              27-Jun-2001 15:10   584k  
[   ] pt-nc.pdf               27-Jun-2001 15:10   569k  
[   ] prt.pdf                 27-Jun-2001 15:01   614k  
[DIR] pi/                     27-Mar-2003 08:55      -  
[   ] htt.pdf                 27-Jun-2001 15:02   582k  
[   ] hmt.pdf                 27-Jun-2001 15:03   570k  
[   ] aptt.pdf                27-Jun-2001 15:03   622k  
[   ] 1900657.02.pdf          24-Jun-2002 14:44   337k  
[   ] 1900656.02.pdf          24-Jun-2002 14:44   334k  
[   ] 1900531.pdf             31-Aug-2001 10:22   120k  
[   ] 1900531.05.pdf          24-Jun-2002 14:34   120k  
[   ] 1900531.04.pdf          20-Mar-2001 08:27   159k  
[   ] 1900528.pdf             20-Mar-2001 08:27   324k  
[   ] 1900523.pdf             20-Mar-2001 08:27   325k  
[   ] 1900032.pdf             20-Mar-2001 08:27   314k  
[   ] 1900028.pdf             31-Aug-2001 10:22   121k  
[   ] 1900028.07.pdf          24-Jun-2002 14:34   120k  
[   ] 1900025_e.pdf           20-Mar-2001 08:31    72k  

This press release contains forward-looking statements regarding future events and the future performance of PharmaNetics that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include risks related to market acceptance, clinical trials and dependence on third party distributors and collaborative partners, including, in particular with regard to the legal proceedings commenced against its development partner, Aventis Pharmaceuticals, which action includes without limitation the following specific risks: material monetary costs associated with the litigation, even if successful; uncertainty of obtaining a favorable outcome; the potentially significant harm to PharmaNetics’ business and financial condition and prospects if it is not successful in timely prosecuting the litigation; jeopardizing strategic relationships with other existing or potential collaborative partners; harmful delays in meeting sales objectives, even if the litigation is successful; and disruption of management time and resources to pursue the litigation.  Information concerning these and other of the factors that could cause results to differ materially from those in the forward-looking statements is contained in the Company’s filings with the Securities and Exchange Commission, including Form 10-K, Form 10-Q and Form 8-K reports.